<DOC>
	<DOCNO>NCT00073307</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy ( include quality life ) , pharmacokinetics BAY43-9006 add Best Supportive Care patient unresectable and/or metastatic renal cell cancer , receive one prior systemic regimen advance disease .</brief_summary>
	<brief_title>Study BAY43-9006 Patients With Unresectable and/or Metastatic Renal Cell Cancer</brief_title>
	<detailed_description>Overall Survival ( OS ) , Patient-reported outcome ( PRO )</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients unresectable and/or metastatic , measurable renal cell carcinoma histologically cytologically documented Patients must one prior systemic therapy advance disease , complete least 30 day longer 8 month prior randomization Patients least one unidimensional measurable lesion CTscan MRI accord Response Evaluation Criteria Solid Tumors ( RECIST ) Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients adequate coagulation , liver kidney function Patients rare subtypes renal cell carcinoma ( RCC ) pure papillary cell tumor , mixed tumor contain predominantly sarcomatoid cell , Bellini carcinoma , medullary carcinoma , chromophobe oncocytic tumor Previous malignancy ( except cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumor , malignancy curatively treat &gt; 2 year prior entry Cardiac arrhythmia require antiarrhythmic , symptomatic coronary artery disease ischemia congestive heart failure Patients history human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Patients history presence metastatic brain meningeal tumor Patients seizure disorder require medication ( antiepileptic ) History organ allograft bone marrow transplant stem cell rescue Patients pregnant breastfeed Women childbearing potential must negative pregnancy test prior drug administration . Both men woman enrol trial must use adequate birth control Patients three follow : ECOG performance status great equal 2 , Abnormally high lactate dehydrogenase , Abnormally high serum hemoglobin , Abnormally high correct serum calcium , Absence prior nephrectomy Excluded therapy medication , previous concomitant : Concurrent anticancer chemotherapy , immunotherapy hormonal therapy except biphosphonates Significant surgery 4 week start study Investigational drug therapy within 30 day Concomitant treatment rifampin St. John 's Wort Prior use Rafkinase inhibitor ( RKI ) , MEK Farnesyl transferase inhibitor Prior use Bevacizumab , drug ( investigational license ) target VEGF/VEGF receptor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Renal Cell Cancer ( RCC )</keyword>
	<keyword>Cancer</keyword>
</DOC>